{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:37:13Z","timestamp":1785775033037,"version":"3.56.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.mayocp.2026.04.018","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:01:59Z","timestamp":1777590119000},"page":"1178-1184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Insights on Attitudes and Treatment of Hyperkalemia"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7322-4692","authenticated-orcid":false,"given":"Biff F.","family":"Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Lerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary G.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Beckrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mayocp.2026.04.018_bib1","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.mayocp.2020.06.014","article-title":"Clinical management of hyperkalemia","volume":"96","author":"Palmer","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"5S","key":"10.1016\/j.mayocp.2026.04.018_bib2","first-page":"S1","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.mayocp.2026.04.018_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"issue":"11","key":"10.1016\/j.mayocp.2026.04.018_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101331","article-title":"Consequences of recurrent hyperkalemia on cardiovascular outcomes and mortality","volume":"3","author":"Bakris","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.mayocp.2026.04.018_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/20543581221149710","article-title":"A new perspective to longstanding challenges with outpatient hyperkalemia: a narrative review","volume":"10","author":"Chiu","year":"2023","journal-title":"Can J Kidney Health Dis"},{"issue":"6","key":"10.1016\/j.mayocp.2026.04.018_bib6","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/MAJ.0000000000000475","article-title":"Underprescription of renin-angiotensin system blockers in moderate to severe chronic kidney disease","volume":"349","author":"Shirazian","year":"2015","journal-title":"Am J Med Sci"},{"issue":"7","key":"10.1016\/j.mayocp.2026.04.018_bib7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jch.13563","article-title":"Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care","volume":"21","author":"Pecoits-Filho","year":"2019","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"10.1016\/j.mayocp.2026.04.018_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12882-022-03054-5","article-title":"Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia","volume":"24","author":"Kanda","year":"2023","journal-title":"BMC Nephrol"},{"issue":"7-8","key":"10.1016\/j.mayocp.2026.04.018_bib9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000531102","article-title":"Discontinuation of renin-angiotensin-aldosterone system inhibitors secondary to hyperkalemia translates into higher cardiorenal outcomes","volume":"54","author":"An","year":"2023","journal-title":"Am J Nephrol"},{"issue":"11","key":"10.1016\/j.mayocp.2026.04.018_bib10","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"issue":"23","key":"10.1016\/j.mayocp.2026.04.018_bib11","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.3390\/jcm10235483","article-title":"Optimization of RAASi therapy with new potassium binders for patients with heart failure and hyperkalemia: rapid review and meta-analysis","volume":"10","author":"Montagnani","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.mayocp.2026.04.018_bib12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1681\/ASN.2020050682","article-title":"Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study","volume":"32","author":"Fu","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.mayocp.2026.04.018_bib13","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1681\/ASN.0000000000000425","article-title":"Estimated effect of restarting renin-angiotensin system inhibitors after discontinuation on kidney outcomes and mortality","volume":"35","author":"Hattori","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.04.018_bib14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10741-020-10069-3","article-title":"Management of RAASi-associated hyperkalemia in patients with cardiovascular disease","volume":"26","author":"Silva-Cardoso","year":"2021","journal-title":"Heart Fail Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2026.04.018_bib15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41581-024-00918-x","article-title":"Diuretics in patients with chronic kidney disease","volume":"21","author":"Agarwal","year":"2025","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1016\/j.mayocp.2026.04.018_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae083","article-title":"Maintained renin-angiotensin-aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study","volume":"17","author":"Rastogi","year":"2024","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.mayocp.2026.04.018_bib17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","volume":"4","author":"Rosano","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"8","key":"10.1016\/j.mayocp.2026.04.018_bib18","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.mayocp.2026.04.018_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/MNH.0000000000000564","article-title":"Potassium binding for conservative and preservative management of chronic kidney disease","volume":"29","author":"Clegg","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"10.1016\/j.mayocp.2026.04.018_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10741-024-10461-3","article-title":"Hyperkalemia management: a multidisciplinary expert panel\u2019s perspective on the role of new potassium binders","volume":"30","author":"Fonseca","year":"2025","journal-title":"Heart Fail Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2026.04.018_bib22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.xkme.2020.04.007","article-title":"Impact of dietary potassium restrictions in CKD on clinical outcomes: benefits of a plant-based diet","volume":"2","author":"Clegg","year":"2020","journal-title":"Kidney Med"},{"issue":"2","key":"10.1016\/j.mayocp.2026.04.018_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/sdi.12348","article-title":"Dietary restrictions in dialysis patients: is there anything left to eat?","volume":"28","author":"Kalantar-Zadeh","year":"2015","journal-title":"Semin Dial"},{"issue":"6","key":"10.1016\/j.mayocp.2026.04.018_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.akdh.2023.10.001","article-title":"Hyperkalemia and plant-based diets in chronic kidney disease","volume":"30","author":"Babich","year":"2023","journal-title":"Adv Kidney Dis Health"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561962618495X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561962618495X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:23:40Z","timestamp":1782905020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002561962618495X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S002561962618495X"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.04.018","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Insights on Attitudes and Treatment of Hyperkalemia","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}]}}